HIV-1 integrase Antibody (IN-2)

Product Discontinued

HIV-1 integrase Antibody (IN-2) Summary

• Immunogen: Bacterially expressed, hexahistidine amino-terminal tagged HIV-1 integrase (IN) protein (clade B, HXB-3 isolate)
• Specificity: Bacterial HIV-1 integrase (IN) protein
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:10-1:2000
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:2000
• Theoretical MW: 32 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Bacterial HIV1 integrase (IN) protein

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS and 30% Glycerol
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Immunogen affinity purified

Notes

Myeloma/fusion partners SP2/0

Alternate Names for HIV-1 integrase Antibody (IN-2)

• IN
• P31

Background

Integrase is an enzyme, a product of the HIV1 Gag/Pol gene; the other two enzymes being reverse transcriptase and protease. The human immunodeficiency virus (HIV-1) uses an enzyme, a so-called integrase, to carry out the integration of its viral DNA into the host chromosome thereby tricking the host cell machinery into making viral proteins. The HIV-1 integrase is a protein of 32 kDa and is composed of three domains. No cellular homologue of HIV integrase has been described, so potential inhibitors to this enzyme could be relatively nontoxic.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for HIV-1 integrase Antibody (NBP1-00584)(2)

Publications using NBP1-00584

• Ikeda T, Symeonides M, Albin JS et al. HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G PLoS Pathog. 2018-04-01 [PMID: 29677220] (WB, Human)
• Davis DA, Soule EE, Davidoff KS et al. Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing Antimicrob Agents Chemother 2012-07-01 [PMID: 22508308] (WB)